Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study
|
|
- Clarissa Mathews
- 5 years ago
- Views:
Transcription
1 2278 Diabetes Volume 66, August 2017 Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study Nordin M.J. Hanssen, 1,2 Jean L.J.M. Scheijen, 1,2 Anders Jorsal, 3,4 Hans-Henrik Parving, 5,6,7 Lise Tarnow, 4,6,8 Peter Rossing, 4,6,7 Coen D.A. Stehouwer, 1,2 and Casper G. Schalkwijk 1,2 Diabetes 2017;66: COMPLICATIONS Methylglyoxal (MGO), a major precursor for advanced glycation end products, is increased in diabetes. In diabetic rodents, inhibition of MGO prevents cardiovascular disease (CVD). Whether plasma MGO levels are associated with incident CVD in people with type 1 diabetes is unknown. We included 159 individuals with persistent normoalbuminuria and 162 individuals with diabetic nephropathy (DN) from the outpatient clinic at Steno Diabetes Center. We measured MGO at baseline and recorded fatal and nonfatal CVD over a median follow-up of 12.3 years (interquartile range years). Data were analyzed by Cox regression, with adjustment for sex, age, HbA 1c,DN, diabetes duration, smoking, systolic blood pressure, antihypertensive medication, and BMI. During follow-up, 73 individuals suffered at least one CVD event (36 fatal and 53 nonfatal). Higher MGO levels were associated with total, fatal, and nonfatal incident CVD (hazard ratios [HRs] 1.47 [95% CI ], 1.42 [ ], and 1.46 [ ], respectively). We observed a similar trend for total mortality (HR 1.24 [ ]). This study shows for the first time in our knowledge that plasma MGO levels are associated with cardiovascular events in individuals with type 1 diabetes. MGO may explain, at least in part, the increased risk for CVD in type 1 diabetes. Individuals with type 1 diabetes have an increased risk of cardiovascular disease (CVD) (1). A key mediator in the association between diabetes and CVD may be the formation of dicarbonyls, which are reactive glucose metabolites that interact with protein residues to form advanced glycation end products (AGEs) (2). Methylglyoxal (MGO), glyoxal (GO), and 3-deoxyglucosone (3-DG) have been identified as major dicarbonyl compounds (3). Of these, MGO has been identifiedasthemostreactivedicarbonylandhas emerged as a key player in the development of diabetic complications (4,5). MGO may contribute to diabetic CVD through several mechanisms, including the development of diabetic nephropathy (DN), endothelial dysfunction (ED) (6), and lowgrade inflammation (LGI) (7). In plaques, MGO induces growth of the necrotic core, predisposing them toward rupture (8). We previously found that the MGO-derived AGE N e (carboxyethyl)lysine (CEL) is associated with incident CVD in type 1 and 2 diabetes (9,10). However, whether plasma levels of MGO are associated with CVD in individuals with diabetes is unknown. Therefore, we investigated whether higher plasma levels of MGO, as well as the other major dicarbonyls GO and 3-DG, in type 1 diabetes are associated with incident CVD and whether the associations with incident CVD are explained by markers of DN, ED, and LGI. RESEARCH DESIGN AND METHODS Study Population and Design In 1993, 199 patients with type 1 diabetes and DN and 192 patients with type 1 diabetes and normoalbuminuria.18 years of age were enrolled in a prospective observational study at the outpatient clinic at Steno Diabetes Center. Patient selection and inclusion criteria are described elsewhere (11). The study was approved by the local ethics 1 Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands 2 CARIM School for Cardiovascular Diseases, Maastricht, the Netherlands 3 Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark 4 Steno Diabetes Center Copenhagen, Gentofte, Denmark 5 Department of Medical Endocrinology, Rigshospitalet, Copenhagen, Denmark 6 Faculty of Health Science, Aarhus University, Aarhus, Denmark 7 Faculty of Health, University of Copenhagen, Copenhagen, Denmark 8 Nordsjællands Hospital, Hillerød, Denmark Corresponding author: Casper G. Schalkwijk, c.schalkwijk@maastrichtuniversity.nl. Received 21 December 2016 and accepted 21 May by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at
2 diabetes.diabetesjournals.org Hanssen and Associates 2279 committee (Gentofte, Denmark) in accordance with the Declaration of Helsinki. All individuals provided informed consent. Measurements of biomarkers for ED and LGI; levels of the major AGEs N e (carboxymethyl)lysine (CML), CEL, and pentosidine; and risk factors are described in detail elsewhere (9). Plasma levels of MGO, GO, and 3-DG were measured with ultra performance liquid chromatography tandem mass spectrometry (12). Measurements of other biomarkers and risk factors are described in detail elsewhere (9,13). Individuals with prior CVD (n = 24), end-stage renal diseaseatbaseline(n = 10), and/or missing follow-up (n = 17) or plasma biomarker (n = 23) data were excluded, resulting in a study population of 321 (DN, n = 162; normoalbuminuria, n = 159). Follow-up and Study End Points All patients were followed until their last visit at Steno Diabetes Center, 1 September 2006, death (n = 81), or emigration (n = 3). All patients were traced through the national register during the autumn of When a patient died before 1 September 2006, the date of death was recorded and the cause of death obtained from the death certificate or necropsy reports when available. Nonfatal CVD information was retrieved from patient files at the Steno Diabetes Center or from other hospital records. In individuals who had more than one CVD event during follow-up, the first event was used in the analyses. Statistical Analyses All analyses were performed with SPSS version 20 for Windows software (IBM Corporation, Chicago, IL). Variables that showed a skewed distribution were natural log (ln)-transformed before analyses. Pearson correlation coefficients were calculated between the plasma dicarbonyls and the ln-transformed plasma AGE levels. An LGI and ED score was calculated as described previously (9). We examined cross-sectional associations by using linear regression analyses. Cox proportional hazards regression models were applied to investigate associations between plasma z scores of MGO, GO, and 3-DG and study end points, with adjustmentforsex,age,durationofdiabetes,hba 1c,andDN status (model 1). Additional adjustments were performed for BMI, systolic blood pressure, total cholesterol, current smoking, and antihypertensive treatment (model 2). Adjustments for the associations for markers of DN (estimated glomerular filtration rate [egfr], and ln urinary albumin excretion [ln-uae]; model 3), ED (model 4), and LGI (model 5) were performed to evaluate the extent to which these pathophysiological processes could explain the associations between dicarbonyls and study outcomes. We investigated whether associations differed between men and women or presence of DN by adding interaction terms to model 2 investigating total CVD and total mortality. RESULTS Table 1 shows participant baseline characteristics. We found that individuals who suffered a CVD event had significantly higher MGO and GO levels at baseline. We also found significantly higher MGO levels in those who died during follow-up. Plasma levels of MGO correlated significantly with GO (r = 0.89; P, 0.01) and 3-DG (r = 0.51; P, 0.01). Plasma levels of MGO correlated significantly with plasma CML (r = 0.41; P, 0.01), CEL (r = 0.36; P, 0.01), and pentosidine (r = 0.43; P, 0.01). Plasma levels of GO correlated significantly with CML (r = 0.34; P, 0.01), CEL (r = 0.20; P, 01), and pentosidine (r = 0.25; P, 0.01). 3-DG correlated significantly with CML (r = 0.13; P = 0.02) but not with CEL (r = 20.02; P = 0.69) or pentosidine (r = 0.07; P = 0.21). Associations of MGO With Markers of DN, ED, and LGI Scores Higher plasma levels of MGO were associated with lower egfr (model 1) (Table 2), which remained borderline significant after additional adjustment (model 2). We observed a trend between higher plasma MGO levels and higher UAE levels. Moreover, higher MGO levels were associated with significantly higher ED and LGI scores. We observed similar but weaker associations for GO levels, whereas 3-DG levels were not associated with markers of DN, ED, or LGI scores. Associations of MGO With Total, Fatal, and Nonfatal Incident CVD After adjustment for sex, age, duration of diabetes, HbA 1c, and presence of DN, higher plasma MGO levels were associated with total, fatal, and nonfatal CVD as well as with total mortality (model 1) (Table 3). Additional adjustment for cardiovascular risk factors did not change the point estimates of these associations in a major way (model 2). Associations between MGO levels and incident CVD and total mortality did not differ between men and women or for individuals with and without DN (all P interaction. 0.1). All associations between plasma MGO levels and incident total, fatal, and nonfatal incident CVD remained largely unchanged overall after adjustment for markers of DN and ED scores (models 3 and 4). Overall, the associations attenuated slightly after we adjusted for LGI scores (model 2 vs. 5). Although glucose is a major precursor for MGO, additional adjustment of model 2 for fasting plasma glucose did not weaken the association between MGO and total CVD (hazard ratio [HR] 1.59 [95% CI ]). Similarly, the omission of HbA 1c from model 2 did not materially change the association between plasma MGO levels and total CVD (HR 1.48 [95% CI ]). Associations of GO With Total, Fatal, and Nonfatal Incident CVD After adjustment for sex, age, duration of diabetes, HbA 1c, and presence of DN, higher GO levels were associated with total and nonfatal CVD (model 1) (Table 3). We observed a borderline significant association with fatal CVD (model 1). Additional adjustment for cardiovascular risk factors did not majorly change the associations (model 2). We did not observe any associations between GO levels and total mortality (models 1 5). Associations between GO levels and incident CVD and total mortality did not differ between
3 2280 Methylglyoxal and CVD in Type 1 Diabetes Diabetes Volume 66, August 2017 Table 1 Baseline characteristics according to total incident CVD and survival status at 12 years of follow-up Characteristic No CVD event (n = 248) CVD event (n = 73) P value Alive (n =240) Dead (n = 81) P value Age (years) , ,0.01 Male sex (%) Duration of diabetes (years) 26.0 ( ) 29.0 ( ), ( ) 28.0 ( ),0.01 HbA 1c (%) , ,0.01 HbA 1c (mmol/mol) , ,0.01 DN (%) , ,0.01 Retinopathy (%),0.01,0.01 None Simple Proliferative BMI (kg/m 2 ) Total cholesterol (mmol/l) , ,0.01 HDL (mmol/l) Triglycerides (mmol/l) 0.8 ( ) 1.2 ( ), ( ) 1.3 ( ),0.01 Serum creatinine (mmol/l) , ,0.01 egfr (ml/min/1.73 m 2 ) , ,0.01 UAE (mg/24 h) 18.0 ( ) (72.5 1,834.5), ( ) ( ,021.0),0.01 Systolic blood pressure (mmhg) , ,0.01 Diastolic blood pressure (mmhg) , ,0.01 Antihypertensive medication (%) , ,0.01 ACE inhibitors (%) , ,0.01 Smoker (%) MGO (nmol/l) , ,0.01 GO (nmol/l) 2, , , , , DG (nmol/l) 4, , , , , , , , CML (mmol/l) 3.5 ( ) 3.5 ( ) ( ) 3.5 ( ) 0.22 CEL (mmol/l) 0.9 ( ) 1.0 ( ), ( ) 1.0 ( ),0.01 Pentosidine (pmol/l) 40.8 ( ) 52.0 ( ), ( ) 51.9 ( ),0.01 Data are mean 6 SD or median (interquartile range) unless otherwise indicated. Differences were tested with a x 2 or Student t test, as appropriate. men and women or for individuals with and without DN (all P interaction. 0.1). Adjustment for markers of DN seemed to strengthen associations between GO and total and nonfatal CVD (model 3). All associations between plasma GO levels and incident total, fatal, and nonfatal incident CVD remained similar overall after adjustment for ED or LGI scores (models 3 5). Associations of 3-DG With Total, Fatal, and Nonfatal Incident CVD Either in crude analyses (Table 1) or after adjustment for potential confounding (Table 3, models 1 and 2) or potential mediating (Table 3, models 3 5) factors, we did not observe any significant associations between plasma 3-DG levels and total and nonfatal incident CVD or total mortality. We did observe a nonsignificant trend between 3-DG levels and fatal CVD. DISCUSSION The main finding of this study was that plasma MGO levels are associated with incident total, fatal, and nonfatal CVD in individuals with type 1 diabetes. We observed similar associations between GO levels and total and nonfatal CVD. Although plasma MGO levels were associated with plasma markers of DN, ED, and LGI, these markers did not seem to mediate large parts of the associations between plasma MGO levels and incident CVD. The associations between plasma MGO levels and markers of DN are in line with a previous report in individuals with type 2 diabetes (14). Many studies have implicated MGO and AGEs in the development of DN (6,7,15,16). Indeed, in an animal model of type 1 diabetes, we found that a reduction of MGO prevents vascular LGI, ED, DN, and retinopathy (15,17). MGO may hamper function of the vasculature through several
4 diabetes.diabetesjournals.org Hanssen and Associates 2281 Table 2 Multivariable standardized b-values (95% CIs) for the cross-sectional associations among plasma dicarbonyls plasma creatinine clearance, ln-uae, ED, and LGI scores Model egfr ln-uae ED LGI MGO (20.21 to 20.02) (20.06 to 0.04) 0.14 (0.03 to 0.25) 0.17 (0.06 to 0.27) (20.18 to 0.01) (20.08 to 0.01) 0.17 (0.06 to 0.28) 0.22 (0.11 to 0.33) GO (20.07 to 0.11) (20.06 to 0.03) (20.11 to 0.10) 0.07 (20.04 to 0.17) (20.05 to 0.14) (20.08 to 0.00) 0.04 (20.07 to 0.15) 0.13 (0.02 to 0.23) 3-DG (20.06 to 0.12) (20.09 to 0.00) (20.15 to 0.07) (20.12 to 0.10) (20.05 to 0.13) (20.08 to 0.01) (20.11 to 0.10) 0.03 (20.07 to 0.14) Data were analyzed by using linear regression analyses. Regression coefficients are expressed as a 1 SD difference in egfr, ln-uae, ED, or LGI score per SD increase of plasma dicarbonyl. Model 1: adjusted for age, sex, diabetes duration, HbA 1c, and presence of DN. Model 2: model 1 + adjustment for total cholesterol, current smoking, and systolic blood pressure and blood pressure lowering treatment. mechanisms, such as impairment of vasodilation (6), inhibition of the proteasome (18), and generation of oxidative stress (6). Moreover, this study is the first to our knowledge that shows an association between plasma MGO levels and incident CVD. One previous study has linked MGO levels with changes in carotid intima-medial thickness in type 2 diabetes (19). The current study also is in line with previous findings demonstrating that MGO-derived AGEs are associated with incident CVD (9,10) and rupture-prone plaques (8,20). Similarly, skin levels of AGEs have been linked to macrovascular disease in the Diabetes Control and Complications Trial (DCCT) (21). The current finding that MGO is associated with incident CVD is in line with AGE intervention studies performed in rodents. Aminoguanidine, an inhibitor of MGO and glycation, reduced atherosclerosis in an experimental model of diabetes (22). Similarly, the AGE-breaker alagebrium, which has MGOquenching properties, reduces atherosclerotic burden (22). Other MGO/AGE-quenching compounds, such as pyridoxamine, reduce atherosclerotic burden in mice and should be evaluated in a human study on cardiovascular outcomes (23). Whether the trans-resveratrol and hesperetin coformulation, which acts as a glyoxalase inducer, reduces vascular disease by inhibiting MGO should be determined (24). In addition to the association between plasma MGO levels and incident CVD, this study reveals that plasma GO levels display similar associations with incident CVD Table 3 Multivariable adjusted HRs (95% CIs) for the associations among plasma dicarbonyls, incident cardiovascular outcomes, and mortality Model Total CVD (n =73) FatalCVD(n = 36) Nonfatal CVD (n = 53) Total mortality (n =81) MGO ( ) 1.37 ( ) 1.54 ( ) 1.25 ( ) ( ) 1.42 ( ) 1.46 ( ) 1.24 ( ) ( ) 1.49 ( ) 1.53 ( ) 1.26 ( ) ( ) 1.41 ( ) 1.46 ( ) 1.24 ( ) ( ) 1.36 ( ) 1.40 ( ) 1.18 ( ) GO ( ) 1.16 ( ) 1.40 ( ) 0.96 ( ) ( ) 1.29 ( ) 1.35 ( ) 1.00 ( ) ( ) 1.35 ( ) 1.49 ( ) 1.03 ( ) ( ) 1.30 ( ) 1.36 ( ) 1.01 ( ) ( ) 1.24 ( ) 1.32 ( ) 0.97 ( ) 3-DG ( ) 1.20 ( ) 0.79 ( ) 1.01 ( ) ( ) 1.37 ( ) 0.88 ( ) 1.16 ( ) ( ) 1.39 ( ) 0.92 ( ) 1.19 ( ) ( ) 1.39 ( ) 0.88 ( ) 1.18 ( ) ( ) 1.34 ( ) 0.88 ( ) 1.15 ( ) Data were analyzed by using Cox proportional hazard regression analyses. HR is expressed per SD increase of plasma dicarbonyl. Model 1: adjusted for age, sex, diabetes duration, HbA 1c, and presence of DN. Model 2: model 1 + adjustment for total cholesterol, BMI, current smoking, and systolic blood pressure and blood pressure lowering treatment. Model 3: model 2 + egfr and ln-uae. Model 4: model 2 + ED (soluble intracellular adhesion molecule [sicam] + soluble vascular cell adhesion molecule). Model 5: model 2 + LGI (sicam + ln-c-reactive protein + ln-interleukin-6 + ln-secretory phospholipase A2).
5 2282 Methylglyoxal and CVD in Type 1 Diabetes Diabetes Volume 66, August 2017 as MGO. We found that adjustment for LGI scores slightly attenuated the associations between MGO and incident CVD. Therefore, MGO may lead to CVD at least partly through LGI. Whether drugs with anti-inflammatory properties mitigate detrimental effects of MGO is unknown. The fact that DN and ED scores did not mediate the association between MGO and CVD should be interpreted with care because we only assessed a limited set of biomarkers. Because MGO fluctuates with plasma glucose levels (25), novel glucose-lowering compounds may be effective treatments to target dicarbonyl stress. Furthermore, MGO has been shown to increase after a mixed meal in diabetes (25) and that obesity and dyslipidemia may also influence MGO levels. Indeed, we identified caloric restriction as a method to greatly reduce MGO levels in obese individuals with type 2 diabetes (25). A major strength of this study is that we used a relatively large sample of individuals with type 1 diabetes with and without microvascular complications. We measured MGO and other markers of dicarbonyl stress with state-of-the-art techniques. However, this study also has several limitations. It did not address where plasma dicarbonyl levels originate. We hypothesize that erythrocytes, endothelial cells, and perhaps plaque macrophages are major sources. Furthermore, the current study was completed in 2006; therefore, we could not investigate whether adjustment for risk modifying drugs, such as statins, at baseline influenced the results. We also cannot exclude that we underestimated the associations because of prolonged storage times of plasma samples and changes in medication use during the follow-up period. Nonetheless, the current study provides an important proof of principle that confirms a large body of experimental evidence identifying MGO as a key player in diabetic complications and CVD. In conclusion, the current study underlines the importance of MGO in type 1 diabetic CVD in humans. Future studies will address whether these findings also hold true for individuals with type 2 diabetes. Furthermore, this study underlines the potential interest of identified inhibitors of MGO formation in curtailing diabetic complications. Funding. This research was supported by the European Foundation for the Study of Diabetes (EFSD/Lilly program 2016). Duality of Interest. No potential conflicts of interest relevant to this article were reported. Author Contributions. N.M.J.H. analyzed data and wrote the manuscript. J.L.J.M.S. measured plasma dicarbonyls and edited the manuscript. A.J. and H.-H.P. collected follow-up data on patients and edited the manuscript. H.-H.P., L.T., and P.R. designed the study and edited the manuscript. C.D.A.S. wrote and edited the manuscript. C.G.S. was the principal investigator and wrote and edited the manuscript. C.G.S. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. References 1. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014;371: Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 1994;94: Maessen DE, Hanssen NM, Scheijen JL, et al. Post glucose load plasma a-dicarbonyl concentrations are increased in individuals with impaired glucose metabolism and type 2 diabetes: the CODAM study. Diabetes Care 2015;38: Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414: Schalkwijk CG. Vascular AGE-ing by methylglyoxal: the past, the present and the future. Diabetologia 2015;58: Brouwers O, Niessen PM, Haenen G, et al. Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia 2010;53: El-Osta A, Brasacchio D, Yao D, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008;205: Hanssen NM, Wouters K, Huijberts MS, et al. Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur Heart J 2014;35: Nin JW, Jorsal A, Ferreira I, et al. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 2011;34: Hanssen NM, Beulens JW, van Dieren S, et al. Plasma advanced glycation end products are associated with incident cardiovascular events in individuals with type 2 diabetes: a case-cohort study with a median follow-up of 10 years (EPIC-NL). Diabetes 2015;64: Tarnow L, Cambien F, Rossing P, et al. Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 1995; 44: Scheijen JL, Schalkwijk CG. Quantification of glyoxal, methylglyoxal and 3-deoxyglucosone in blood and plasma by ultra performance liquid chromatography tandem mass spectrometry: evaluation of blood specimen. Clin Chem Lab Med 2014;52: Astrup AS, Tarnow L, Rossing P, Pietraszek L, Riis Hansen P, Parving HH. Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int 2005;68: JensenTM,VistisenD,FlemingT,etal.Methylglyoxalisassociatedwith changes in kidney function among individuals with screen-detected type 2 diabetes mellitus. Diabet Med 2016;33: Brouwers O, Niessen PM, Miyata T, et al. Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes. Diabetologia 2014;57: Geoffrion M, Du X, Irshad Z, et al. Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocintreated, apolipoprotein E-deficient mice. Physiol Rep 2014;2:e Berner AK, Brouwers O, Pringle R, et al. Protection against methylglyoxalderived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia 2012;55: Queisser MA, Yao D, Geisler S, et al. Hyperglycemia impairs proteasome function by methylglyoxal. Diabetes 2010;59: Ogawa S, Nakayama K, Nakayama M, et al. Methylglyoxal is a predictor in type 2 diabetic patients of intima-media thickening and elevation of blood pressure. Hypertension 2010;56: van Eupen MG, Schram MT, Colhoun HM, et al. The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with svcam-1. Diabetologia 2013;56: Monnier VM, Bautista O, Kenny D, et al.; DCCT Skin Collagen Ancillary Study Group; Diabetes Control and Complications Trial. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive
6 diabetes.diabetesjournals.org Hanssen and Associates 2283 versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA 1c as markers of diabetic complications. Diabetes 1999;48: Forbes JM, Yee LT, Thallas V, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis [published correction appears in Diabetes 2006;55:862]. Diabetes 2004;53: Watson AM, Soro-Paavonen A, Sheehy K, et al. Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 2011;54: Xue M, Weickert MO, Qureshi S, et al. Improved glycemic control and vascular function in overweight and obese subjects by glyoxalase 1 inducer formulation. Diabetes 2016;65: Maessen DE, Hanssen NM, Lips MA, et al. Energy restriction and Roux-en-Y gastric bypass reduce postprandial a-dicarbonylstressinobesewomenwithtype2 diabetes. Diabetologia 2016;59:
COMPLICATIONS. Diabetes Volume 64, January Diabetes 2015;64: DOI: /db
Diabetes Volume 64, January 2015 257 Nordin M.J. Hanssen, 1,2 Joline W.J. Beulens, 3 Susan van Dieren, 3 Jean L.J.M. Scheijen, 1,2 Daphne L. van der A, 4 Annemieke M.W. Spijkerman, 4 Yvonne T. van der
More informationDiabetes Care 2015;38: DOI: /dc OBJECTIVE RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS. Diabetes Care Volume 38, May
Diabetes Care Volume 38, May 2015 913 Post Glucose Load Plasma a-dicarbonyl Concentrations Are Increased in Individuals With Impaired Glucose Metabolism and Type 2 Diabetes: The CODAM Study Dionne E. Maessen,
More informationMarkers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years
Pathophysiology/Complications O R I G I N A L A R T I C L E Markers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years Association
More informationThe metabolic memory. Antonio Ceriello
The metabolic memory Antonio Ceriello : DCCT/EDIC - Long-term Microvascular Risk Reduction in Type 1 Diabetes A1C 12% 10% Intensive Retinopathy progression (incidence) Conventional 0.5 0.4 0.3 62% risk
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationRecent studies have suggested a potential role of
BRIEF REPORT Higher Plasma Soluble Receptor for Advanced Glycation End Products (srage) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes A 12-Year Follow-Up
More informationClinical Study Factors Associated with the Decline of Kidney Function Differ among egfr Strata in Subjects with Type 2 Diabetes Mellitus
International Endocrinology Volume 2012, Article ID 687867, 6 pages doi:10.1155/2012/687867 Clinical Study Factors Associated with the Decline of Kidney Function Differ among egfr Strata in Subjects with
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationOBJECTIVE RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS. Diabetes Care 1 PATHOPHYSIOLOGY/COMPLICATIONS
Diabetes Care 1 Increased All-Cause Mortality in Patients With Type 1 Diabetes and High-Expression Mannan-Binding Lectin Genotypes: A 12-Year Follow-up Study DOI: 10.2337/dc15-0851 Jakob A. Østergaard,
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationAutonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationStandards of Medical Care in Diabetes 2016
Standards of Medical Care in Diabetes 2016 Care Delivery Systems 33-49% of patients still do not meet targets for A1C, blood pressure, or lipids. 14% meet targets for all A1C, BP, lipids, and nonsmoking
More informationCardiovascular Diabetology. Open Access ORIGINAL INVESTIGATION. C. R. L. Cardoso 1, N. C. Leite 1, C. B. M. Moram 2 and G. F.
https://doi.org/10.1186/s12933-018-0677-0 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Long term visit to visit glycemic variability as predictor of micro and macrovascular complications
More informationSerum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes an inception cohort study
Diabetes Publish Ahead of Print, published online May 1, 2009 Uric acid and development of diabetic nephropathy Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More information12. GLYCATION AND AGE IN DIABETES AND COMPLICATIONS
12. GLYCATION AND AGE IN DIABETES AND COMPLICATIONS Dr. Zdenka Turk Vuk Vrhovac University Clinic, Zagreb, Croatia Epidemiological studies have confirmed that hyperglycaemia is the most important factor
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationAssociation between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese
Diabetes Care Publish Ahead of Print, published online June 12, 2008 Raised Blood Pressure and Dysglycemia Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Bernard My Cheung,
More informationARTICLE. H. L. Lutgers & E. G. Gerrits & R. Graaff & T. P. Links & W. J. Sluiter & R. O. Gans & H. J. Bilo & A. J. Smit
DOI 10.1007/s00125-009-1308-9 ARTICLE Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type
More informationBariatric Surgery versus Intensive Medical Therapy for Diabetes 3-Year Outcomes
The new england journal of medicine original article Bariatric Surgery versus Intensive Medical for Diabetes 3-Year Outcomes Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., John P. Kirwan, Ph.D.,
More informationDiabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions
Diabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions Diabetes is one of the largest global health emergencies of 21 st century, with the number of people with
More informationThe Metabolic Memory : The New Challenge in The Therapy of Diabetes.
The Metabolic Memory : The New Challenge in The Therapy of Diabetes. Insititut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain Antonio Ceriello EDIC - AIMS Examine the longer-term
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationNon-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus
Diabetologia (2011) 54:73 77 DOI 10.1007/s00125-010-1945-z SHORT COMMUNICATION Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus S. van Dieren & U. Nöthlings & Y.
More informationPeggy Roestenberg - The role of CTGF in diabetic nephropathy
Peggy Roestenberg - The role of CTGF in diabetic nephropathy Chapter 4 Plasma levels of connective tissue growth factor correlate with clinical markers of renal disease in type 1 diabetic patients with
More informationCardiovascular Diabetology. Open Access ORIGINAL INVESTIGATION
DOI 10.1186/s12933-017-0539-1 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all cause mortality
More informationCONTROLLO GLICEMICO NEL PAZIENTE CON DMT2: E' SUFFICIENTE HbA1C? Contrario. Antonio Ceriello a,b
CONTROLLO GLICEMICO NEL PAZIENTE CON DMT2: E' SUFFICIENTE HbA1C? Contrario Antonio Ceriello a,b Excessive Glucose Fluctuations With Same A1C Values 400 Mean A1C = 6.7% Glucose Concentration (mg/dl) 300
More informationSerum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
More informationMethylglyoxal Level In Type-2 Diabetes Mellitus Patients: A Prospective, Randomized and Case Control S
Methylglyoxal Level In Type-2 Diabetes Mellitus Patients: A Prospective, Randomized and Case Control S Methylglyoxal Level In Type-2 Diabetes Mellitus Patients: A Prospective, Randomized and Case Control
More informationMagnetic resonance imaging, image analysis:visual scoring of white matter
Supplemental method ULSAM Magnetic resonance imaging, image analysis:visual scoring of white matter hyperintensities (WMHI) was performed by a neuroradiologist using a PACS system blinded of baseline data.
More informationAnti-Heat Shock Protein 27 Antibody Levels and Diabetic Complications in the EURODIAB Study
Diabetes Care Publish Ahead of Print, published online April 14, 2009 HSP27 antibodies and Diabetic Complications Anti-Heat Shock Protein 27 Antibody Levels and Diabetic Complications in the EURODIAB Study
More informationDepressie en cognitie bij type 2 diabetes. Miranda Schram afdeling Interne Geneeskunde MUMC+
Depressie en cognitie bij type 2 diabetes Miranda Schram afdeling Interne Geneeskunde MUMC+ Disclosure potential conflicts of interest Geen (potentiële) belangenverstrengeling Voor bijeenkomst mogelijk
More informationSHORT COMMUNICATION. Diabetologia (2013) 56: DOI /s
Diabetologia (2013) 56:1542 1546 DOI 10.1007/s00125-013-2914-0 SHORT COMMUNICATION The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (supar) is associated with incident type
More informationClinical Practice Guideline Key Points
Clinical Practice Guideline Key Points Clinical Practice Guideline 2008 Key Points Diabetes Mellitus Provided by: Highmark Endocrinology Clinical Quality Improvement Committee In accordance with Highmark
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationA high concentration of prorenin in early pregnancy is associated with development of pre-eclampsia in women with type 1 diabetes
Diabetologia (2011) 54:1615 1619 DOI 10.1007/s00125-011-2087-7 SHORT COMMUNICATION A high concentration of prorenin in early pregnancy is associated with development of pre-eclampsia in women with type
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationPlasma levels of advanced glycation endproducts are associated with type 1 diabetes and coronary artery calcification
van Eupen et al. Cardiovascular Diabetology 2013, 12:149 CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Plasma levels of advanced glycation endproducts are associated with type 1 diabetes
More informationA large body of epidemiological evidence and animal experimentation underlay the hypothesis that COMPLICATIONS
266 Diabetes Volume 64, January 2015 Saul Genuth, 1 Wanjie Sun, 2 Patricia Cleary, 2 Xiaoyu Gao, 2 David R. Sell, 3 John Lachin, 2 The DCCT/EDIC Research Group,* and Vincent M. Monnier 3,4 Skin Advanced
More informationSTABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
More informationIGFBP-4 Fragments as Markers of Cardiovascular Mortality in Type 1 Diabetes Patients With and Without Nephropathy
ORIGINAL ARTICLE IGFBP-4 Fragments as Markers of Cardiovascular Mortality in Type 1 Diabetes Patients With and Without Nephropathy Rikke Hjortebjerg, Lise Tarnow, Anders Jorsal, Hans-Henrik Parving, Peter
More information300 Biomed Environ Sci, 2018; 31(4):
300 Biomed Environ Sci, 2018; 31(4): 300-305 Letter to the Editor Combined Influence of Insulin Resistance and Inflammatory Biomarkers on Type 2 Diabetes: A Population-based Prospective Cohort Study of
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationSupplementary Online Content
Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.
More informationTubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy
http://www.kidney-international.org & 2011 International Society of Nephrology original article see commentary on page 1042 Tubular markers do not predict the decline in glomerular filtration rate in type
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationSupplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures
Supplementary Data Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Quintiles of Systolic Blood Pressure Quintiles of Diastolic Blood Pressure Q1 Q2
More informationSerum Retinol-binding Protein 4 Levels in Patients with Diabetic Retinopathy
The Journal of International Medical Research 2010; 38: 95 99 Serum Retinol-binding Protein 4 Levels in Patients with Diabetic Retinopathy Z-Z LI 1, X-Z LU 2, J-B LIU 1 AND L CHEN 1 1 Department of Endocrinology,
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationInflammatory Biomarkers (Il-18, Hs-Crp) and Serum Lipids: A Novel Approach to Screen Early Diabetic Nephropathy
Inflammatory Biomarkers (Il-18, Hs-Crp) and Serum Lipids: A Novel Approach to Screen Early Diabetic Nephropathy Dr. Yeshavanth G 1*, Dr. Sachin Bongale 2 1* MBBS, MD, S.S. institute of medical sciences
More informationOriginal Policy Date 12:2013
MP 2.04.73 Non-Invasive Measurement of Advanced Glycation Endproducts (AGEs) in the Skin Medical Policy Section Medicine Issue 12:2013 Subsection Original Policy Date 12:2013 Last Review Status/Date Created
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationAGING KIDNEY IN HIV DISEASE
AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV
More informationORIGINAL INVESTIGATION. Mannose-Binding Lectin and Mortality in Type 2 Diabetes
ORIGINAL INVESTIGATION Mannose-Binding Lectin and Mortality in Type 2 Diabetes Troels Krarup Hansen, MD, PhD; Mari-Anne Gall, MD, DMSc; Lise Tarnow, MD, DMSc; Steffen Thiel, PhD; Coen D. Stehouwer, MD,
More informationPlasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationNephropathy in Type 1 Diabetes: Can One Identity the Patients at Risk?
Nephropathy in Type 1 Diabetes: Can One Identity the Patients at Risk? Pierre Lefèbvre University of Liège, Belgium Cuba, November 2007 Nephropathy in Type 1 Diabetes It has been known for years that the
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationΟ ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη
Ο ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη Κωνσταντίνος Τζιόμαλος Επίκουρος Καθηγητής Παθολογίας Α Προπαιδευτική Παθολογική Κλινική, Νοσοκομείο
More informationSupplementary Online Content
Supplementary Online Content Xu X, Qin X, Li Y, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease: the Renal Substudy of the China Stroke Primary Prevention Trial. JAMA
More information7Progression and regression:
7Progression and regression: Distinct developmental patterns of diabetic retinopathy in patients with type 2 diabetes treated in the Diabetes Care System West-Friesland, the Netherlands Hata Zavrelova,
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationNon alcoholic fatty liver disease and atherosclerosis Raul Santos, MD
Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD Sao Paulo Medical School Hospital Sao Paulo, Brazil Disclosure Honoraria received for consult and/or speaker : Astra Zeneca, Amgen,
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study
ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study Statistical modelling details We used Cox proportional-hazards
More informationDiabetes and Kidney Disease. Kris Bentley Renal Nurse practitioner 2018
Diabetes and Kidney Disease Kris Bentley Renal Nurse practitioner 2018 Aims Develop an understanding of Chronic Kidney Disease Understand how diabetes impacts on your kidneys Be able to recognise the risk
More informationTriglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study
1/5 Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study Jennifer S. Lee, Po-Yin Chang, Ying Zhang, Jorge
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationSchöttker et al. BMC Medicine (2016) 14:26 DOI /s
Schöttker et al. BMC Medicine (2016) 14:26 DOI 10.1186/s12916-016-0570-1 RESEARCH ARTICLE HbA 1c levels in non-diabetic older adults No J-shaped associations with primary cardiovascular events, cardiovascular
More informationEzetimibe Reduces Urinary Albumin Excretion in Hypercholesterolaemic Type 2 Diabetes Patients with Microalbuminuria
The Journal of International Medical Research 2012; 40: 798 803 Ezetimibe Reduces Urinary Albumin Excretion in Hypercholesterolaemic Type 2 Diabetes Patients with Microalbuminuria T NAKAMURA 1, E SATO
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationRisk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study
Indian J Med Res 136, July 2012, pp 46-53 Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study Vijay Viswanathan, Priyanka Tilak
More informationDementia. Inhibition of vascular calcification
FLEMENGHO Dementia Inhibition of vascular calcification Role of matrix Gla protein Yan-Ping Liu, Fang-Fei Wei, Cees Vermeer, and Jan A. Staessen, Research Unit Hypertension and Cardiovascular Epidemiology,
More informationA study of micro vascular complications and associated risk factors in newly diagnosed patients of type 2 diabetes mellitus
International Journal of Community Medicine and Public Health Prakash B et al. Int J Community Med Public Health. 2018 Jun;5(6):2338-2343 http://www.ijcmph.com pissn 2394-6032 eissn 2394-6040 Original
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationSleep Apnea: Vascular and Metabolic Complications
Sleep Apnea: Vascular and Metabolic Complications Vahid Mohsenin, M.D. Professor of Medicine Yale University School of Medicine Director, Yale Center for Sleep Medicine Definitions Apnea: Cessation of
More informationFive chapters 1. What is CVD prevention 2. Why is CVD prevention needed 3. Who needs CVD prevention 4. How is CVD prevention applied 5. Where should CVD prevention be offered Shorter, more adapted to clinical
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More informationLucia Cea Soriano 1, Saga Johansson 2, Bergur Stefansson 2 and Luis A García Rodríguez 1*
Cea Soriano et al. Cardiovascular Diabetology (2015) 14:38 DOI 10.1186/s12933-015-0204-5 CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Cardiovascular events and all-cause mortality in
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationCardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G
More informationHbA1c is associated with intima media thickness in individuals with normal glucose tolerance
Diabetes Care Publish Ahead of Print, published online October 6, 2009 Glucose metabolism and IMT HbA1c is associated with intima media thickness in individuals with normal glucose tolerance Thomas Bobbert,
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationPROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationhttp://noodlemaz.wordpress.com/category/science/cancer/ Outline Introduction Serious nature of Cardiovascular Disease (CVD) How to prevent CVD? The disease process Damage and plaque development Current
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More information